• Maravai LifeSciences highlighted a turnaround from COVID-driven revenue to a streamlined growth platform, citing cost cuts above $65 million.
• Reported 1H 2026 revenue of USD 117.3 million, up 24%, with adjusted gross margin of 62.5%.
• Posted 1H adjusted EBITDA of USD 29 million, returning to positive levels; cited a USD 50 million improvement versus 1H 2025.
• Pointed to base revenue growth of 9% year over year, excluding USD 14.3 million of COVID GMP CleanCap revenue in Q1.
• Outlined priorities in commercial execution, operational excellence, and R&D focus at TriLink and Cygnus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maravai LifeSciences Holdings Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.